Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02880345
Title RADVAX: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy
Recruitment Withdrawn
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Abramson Cancer Center of the University of Pennsylvania
Indications

transitional cell carcinoma

Therapies

Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.